Literature DB >> 2471572

Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation.

C R Chapple1, M L Aubry, S James, P M Greengrass, G Burnstock, R T Turner-Warwick, E J Milroy, M J Davey.   

Abstract

Benign prostatic enlargement is a common cause of bladder outlet obstruction. Recent work has demonstrated the important role played by the sympathetic nervous system in the control of prostatic muscle tone. Although isometric muscle strip studies and clinical trials have highlighted the influence of alpha-1 adrenoceptors, radioisotope ligand binding studies have demonstrated a relatively increased density of alpha-2 adrenoceptors in the muscle within prostatic tissue, the significance of which is as yet unexplained. Forty patients entered a study using pharmacological muscle strip experiments, radioligand binding assays and receptor autoradiography. Pharmacological data from these studies confirmed that contraction of prostatic muscle is mediated predominantly by alpha-1 adrenoceptor stimulation, with no evidence of significant alpha-2 adrenoceptor or cholinergic mediated effects. Radioligand binding studies confirmed that there is a higher concentration of alpha-1 binding sites as contrasted to alpha-2 within normal prostate, but that this relationship approaches equity in adenomatous prostate. Autoradiographic localisation demonstrated that alpha-1 adrenoceptor binding is predominant within prostatic stroma with only a small component of alpha-2 adrenoceptors in this compartment. This comprehensive study supports the suggestion that prostatic muscular contraction is controlled by the influence of the sympathetic nervous system acting via alpha-1 adrenoceptors. These findings support the therapeutic use of specific alpha-1 adrenoceptor blockade in the management of benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471572     DOI: 10.1111/j.1464-410x.1989.tb05942.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  15 in total

1.  Medical treatment for benign prostatic hyperplasia.

Authors:  C Chapple
Journal:  BMJ       Date:  1992-05-09

2.  Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053.

Authors:  I Marshall; R P Burt; G M Green; M B Hussain; C R Chapple
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 3.  Endocrine and adrenergic pharmacological intervention in diseases of the prostate.

Authors:  A Rane
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

4.  Identification of alpha 1-adrenoceptor subtypes in the dog prostate.

Authors:  T Ohmura; S Sakamoto; H Hayashi; S Kigoshi; I Muramatsu
Journal:  Urol Res       Date:  1993-05

5.  Anatomy of the prostatic nerves.

Authors:  G Benoit; L Merlaud; G Meduri; M Moukarzel; J Quillard; M Ledroux; F Giuliano; A Jardin
Journal:  Surg Radiol Anat       Date:  1994       Impact factor: 1.246

Review 6.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

7.  Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).

Authors:  S Dutkiewicz; A Witeska
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

8.  Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype.

Authors:  I Marshall; R P Burt; C R Chapple
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  Noradrenergic vasoconstriction of pig prostatic small arteries.

Authors:  Paz Recio; Luis M Orensanz; María Pilar Martínez; Jorge Navarro-Dorado; Salvador Bustamante; Albino García-Sacristán; Dolores Prieto; Medardo Hernández
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 10.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.